NCT07020377 - Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM). | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 15, 2024

Primary Completion Date

December 20, 2025

Study Completion Date

December 30, 2025

Conditions

Diabetes MellitusNon Alcholic Fatty Liver Disease

Interventions

DRUG

Dapagliflozin (DAPA)

dapagliflozin 10mg tab once daily for NAFLD patient

DRUG

Placebo

placebo

OTHER

Negative control

Baseline sample serum without either drug or placebo

Trial Locations (2)

Egyptian liver hospital, Al Mansurah

Alexandria university main hospital, Alexandria

All Listed Sponsors

collaborator

Alexandria University

OTHER

collaborator

Egyptian Liver Hospital

OTHER

lead

Amira Bisher,PhD

OTHER